Virbac Overview
- Year Founded
-
1968
- Status
-
Public
- Employees
-
50
- Stock Symbol
-
VIRP
- Investments
-
16
- Share Price
-
$393.02
- (As of Monday Closing)
Virbac General Information
Description
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
Contact Information
Website
corporate.virbac.comCorporate Office
- 13e rue LID
- BP 27
- 06511 Carros
- France
Corporate Office
- 13e rue LID
- BP 27
- 06511 Carros
- France
Virbac Stock Performance
As of 16-Nov-2026, Virbac’s stock price is $393.02. Its current market cap is $3.29B with 8.38M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $393.02 | $391.71 | $340.82 - $458.83 | $3.29B | 8.38M | 5.39K | $21.70 |
Virbac Financials Summary
As of 30-Jun-2026, Virbac has a trailing 12-month revenue of $1.74B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,371,982 | 3,748,479 | 3,014,921 | 3,270,286 |
| Revenue | 1,743,194 | 1,652,165 | 1,512,102 | 1,349,241 |
| EBITDA | 340,923 | 317,850 | 291,903 | 240,037 |
| Net Income | 181,805 | 170,201 | 157,218 | 131,254 |
| Total Assets | 2,375,443 | 2,248,417 | 1,923,520 | 1,609,164 |
| Total Debt | 408,647 | 339,266 | 319,470 | 132,770 |
Virbac Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Virbac Patents
Virbac Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-3173466-A1 | Veterinary oral medicinal composition | Pending | 30-Apr-2025 | ||
| FR-3173464-A3 | Veterinary oral medicinal composition | Pending | 26-Mar-2025 | ||
| FR-3173465-A1 | Veterinary oral medicinal composition | Pending | 26-Mar-2025 | ||
| WO-2026202141-A1 | Veterinary oral medicinal composition | Pending | 26-Mar-2025 | ||
| FR-3169909-A1 | An undirected, constrained, and accelerated process for modifying pathogenic bacterial strains for the preparation of live attenuated vaccines and resulting strains | Pending | 12-Dec-2024 | A61K39/092 |
Virbac Signals
Virbac Investments & Acquisitions (16)
Virbac’s most recent deal was a Corporate Asset Purchase with Norbrook Laboratories (Feline Hyperthyroidism Drug) for . The deal was made on 16-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Norbrook Laboratories (Feline Hyperthyroidism Drug) | 16-Dec-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Mopsan Veterinary Products | 02-Dec-2024 | Merger/Acquisition | Distributors (Healthcare) | ||
| Globion | 21-Jun-2024 | Secondary Transaction - Private | Other Consumer Non-Durables | ||
| Sasaeah | 01-Apr-2024 | Merger/Acquisition | Other Consumer Non-Durables | ||
| Globion | 01-Nov-2023 | Merger/Acquisition | Other Consumer Non-Durables |
Virbac ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
17.79 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Virbac Exits (1)
Virbac’s most recent exit was on 02-Jan-2015 from Eli Lilly (Rights and Titles of Sentinel Flavor Tabs and Sentinel Spectrum). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Eli Lilly (Rights and Titles of Sentinel Flavor Tabs and Sentinel Spectrum) | 02-Jan-2015 | Completed |
|
Virbac Affiliates
Subsidiaries (13)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sasaeah | Shinagawa, Japan | 2020 | |
| Norbrook Laboratories (Feline Hyperthyroidism Drug) | Newry, United Kingdom | 2016 | |
| Globion | Secunderabad, India | 2005 | |
| Ivet (Internet Retail) | Parkville, MO | 2002 | |
| Mopsan Veterinary Products | Atasehir, Turkey | 1993 |
Virbac FAQs
-
When was Virbac founded?
Virbac was founded in 1968.
-
Where is Virbac headquartered?
Virbac is headquartered in Carros, France.
-
What is the size of Virbac?
Virbac has 50 total employees.
-
What industry is Virbac in?
Virbac’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Virbac a private or public company?
Virbac is a Public company.
-
What is Virbac’s stock symbol?
The ticker symbol for Virbac is VIRP.
-
What is the current stock price of Virbac?
As of 16-Nov-2026 the stock price of Virbac is $393.02.
-
What is the current market cap of Virbac?
The current market capitalization of Virbac is $3.29B.
-
What is Virbac’s current revenue?
The trailing twelve month revenue for Virbac is $1.74B.
-
What is Virbac’s annual earnings per share (EPS)?
Virbac’s EPS for 12 months was $21.70.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process